Keros Therapeutics (KROS) to Release Earnings on Wednesday

Keros Therapeutics (NASDAQ:KROS) is expected to be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $3.6620 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Keros Therapeutics Stock Down 2.1%

Shares of NASDAQ KROS opened at $16.20 on Monday. The firm’s 50-day moving average price is $18.85 and its two-hundred day moving average price is $17.08. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $22.55. The stock has a market capitalization of $493.61 million, a P/E ratio of 10.52 and a beta of 0.86.

Institutional Trading of Keros Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its stake in Keros Therapeutics by 149.2% during the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares in the last quarter. XTX Topco Ltd bought a new stake in Keros Therapeutics in the fourth quarter worth about $212,000. New York State Common Retirement Fund lifted its holdings in Keros Therapeutics by 264.1% in the 2nd quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after acquiring an additional 7,700 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new position in shares of Keros Therapeutics during the 3rd quarter valued at about $176,000. Finally, Virtus Investment Advisers LLC grew its stake in shares of Keros Therapeutics by 48.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 12,367 shares of the company’s stock worth $252,000 after purchasing an additional 4,025 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently commented on KROS. Zacks Research lowered shares of Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 1st. Oppenheimer reissued an “outperform” rating and set a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Wells Fargo & Company cut their price target on Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $22.29.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.